@article{5202,
  keywords = {Antibody Formation, Cyclophosphamide, Dapsone, Immunochemistry, leprosy, Leukocyte Count, Leukopenia, Pharmacology, South Africa, Streptomycin, toxicology},
  author = {Davison A R and Schulz E J and Falkson G and Egnal M L},
  title = {Effect of Cyclophosphamide on Leprosy. Competitive Action of Cyclophosphamide and Dapsone.},
  abstract = {<p>Cyclophosphamide is a propylene phosphoric ester diamide which is used in the treatment of neoplasms, though it is limited by the development of leucopenia. One of the authors (G. Falkson), in 1960, saw a leprosy patient who had been given Cyclophosphamide because of mistaken diagnosis of mycosis fungoides. The dermal infiltration and the neuritic symptoms of the leprosy patient had diminished with treatment. Accordingly 8 Bantu patients, at Westfort Institution, Pretoria, were given Cyclophosphamide intravenously in doses varying from 400 to 800 mgm. daily, followed, in 4 patients, by 100 mgm. daily by mouth. In 4 patients who received dapsone together with Cyclophosphamide, the leucopenic effect of the latter was inhibited. There was 1 patient with lepromatous leprosy who received only Cyclophosphamide for a long time; he benefited considerably. There is evidence that Cyclophosphamide may inhibit acute reactions in leprosy. The results are tabulated.</p>
},
  year = {1964},
  journal = {Lancet (London, England)},
  volume = {2},
  pages = {1138-41},
  month = {1964 Nov 28},
  issn = {0140-6736},
  doi = {10.1016/s0140-6736(64)92664-9},
  language = {eng},
}